Merrill Lynch Reiterates a Buy Rating on Charles River LabsBy Austin Angelo
According to TipRanks.com, Bruin is a 3-star analyst with an average return of 3.8% and a 55.1% success rate. Bruin covers the Healthcare sector, focusing on stocks such as Quintiles Transnational, Becton Dickinson, and Genomic Health.
Charles River Labs has an analyst consensus of Hold, with a price target consensus of $85.
Charles River Labs ‘s market cap is currently $3.49B and has a P/E ratio of 24.82. The company has a book value ratio of 4.0189.
Based on the recent corporate insider activity of 78 insiders, corporate insider sentiment is negative on the stock. Most recently, in September 2016, Davide Molho, the Corporate Executive VP of CRL sold 7,877 shares for a total of $662,428.
Charles River Laboratories International, Inc. is an early-stage contract research company, which provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe to accelerate their research and drug development efforts. It operates through the following business segments: Research Models and Services, Discovery and Safety Assessment, and Manufacturing Support. The Research Models and Services segment comprises of the production and sale of research models, and also offers services designed to support to clients use of research models in screening drug candidates. The Discovery and Safety Assessment segment offers discovery and safety assessment services, both regulated and non-regulated, in which it include both in vivo and in vitro studies, supporting laboratory services, and strategic preclinical consulting and program management to support product development. The Manufacturing Support segment offers endotoxin and microbial detection, avian vaccine services and biologics testing solutions. The company was founded by Henry L. Foster in 1947 and is headquartered in Wilmington, MA.